Pol. Noain-Esquiroz, C/S, Nave 4
(+34)633 674 251
info@genbioma.com
Specialized in research and development services to develop new solutions in the field of probiotics and other bioactive compounds with demonstrated properties for human health.
Our mission is to contribute to the improvement of human health by utilizing our talents and capabilities for probiotics and bioactive compounds research and development. Dietary supplement industries and food industry are our main partners. Our first goal is to leverage the central role of probiotics and the gut microbiota on the glycemic regulation in prediabetes. Our lead Project is a dietary supplement designed by using specific strains selected for its potential ability for long-term glycemic regulation that aims at offering a complementary strategy to people in early stages of diabetes.
Different ways to partnership with the goal to cover your specific needs. We are a B2B provider for Dietary Supplements & Food Industry.
If you want to become one of our partners, please contact us.
(+34)633 674 251
Proven effectiveness of probiotics for glycemia regulation.
Genbioma develops its own probiotic supplements based on objective measurable criteria which are the result of research and/or trials on:
Prediabetes is defined as blood glucose levels above normal but below that of diabetes. The prevalence in the world exceeds 25%, who are at high risk of developing type 2 diabetes and a higher chance of experiencing serious complications from COVID-19. Prediabetes is a global important public health problem. The number of prediabetic people may triple that of diabetics. Costs associated with this condition are almost USD 50 Bn in the US alone.
The scientific evidence has shown that the human gut microbiota has emerged as a key factor in the development of diabetes. The potential benefits of using probiotics for the regulation of hyperglycemia have been supported and might provide an important strategy to combat diabetes risk.
Our strains have promising potential to be developed as a valuable supplement in reducing specific markers of diabetes and is poised to have significant relevance in conditions of heightened blood glucose, such as early stages of diabetes.
Genbioma: aims to a reference in the Premium Probiotics market with this first probiotic supplement for long term regulation of normal blood glucose levels.
pA1c
pA1c is the first Genbioma´s benchmark strain for pharma and nutrition brands. The innovation is based on scientific dossiers supporting its long-term blood sugar regulating effect and the potential interest for prediabetes and diabetes managment.
REGLUBETIC
Reglubetic is a daily oral probiotic supplement on long-term glycaemic control in otherwise healthy hyperglycaemic people.
The solution is a breakthrough in microbiome science based on pA1c strain and its ability to manage blood sugar levels. Modification of gut microbiota by probiotic supplementation may be a method for preventing and control hyperglycaemia.
Our patented strain formulation cannot be found in any other probiotic on the market.
Current Study: Contribute to furthering science advancement:
Evaluation of the effect of Reglubetic on glycaemic control, insulin resistance and the composition of the microbiota in healthy hyperglycaemic adults. Research agreement with the Centre for Nutrition Research - University of Navarra.
The only way that this can be tested for effectiveness is with the help of volunteers. Would you like to join our clinical trial?
Eligibility Criteria:
Please complete the Pre-Screening Questionnaire to help us determine your eligibility for the trial, indicating PREDIABETCARE.
Click here
Or send an email indicating PREDIABETCARE to voluntariosnut@unav.es
Genbioma is a research platform for probiotic and bioactive compounds studies, focused on understanding its potential to improve or maintain health in target populations.
The research includes the selection, identification, scale-up and production of our patented strain collection, in vitro and in vivo pre-clinical studies in animal models as well as clinical trials in humans, to evaluate food safety and health benefits of probiotics and other bioactive compounds for specific health purposes.
Clinical trials (mainly nutritional intervention trials to prediabetic population) performed in collaboration with prestigious research centres to further develop and extend the clinical documentation and probiotic applications.
The company has one patent pending approval to protect our company intellectual property.
